In a talk at the meeting, Riken's Piero Carninci described the RADICL-seq tool he and his colleagues developed.
Independent research teams identified and sequenced hepatitis B strains going back thousands of years from samples in Europe, uncovering now-extinct lineages.
Despite the astronomical costs, it may prove challenging to reverse course and discontinue Zika testing according to a commentary article accompanying a NEJM study.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The company said 677 of its GPS Cancer commercial tests were ordered in Q1 2018, up from 606 in Q4 2017.
Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.
The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.
VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.
A new study suggests that enhanced tumor clone frequencies, found by T cell receptor beta gene sequencing, coincide with poorer mycosis fungoides outcomes.
Using genome sequences for hundreds of ancient individuals, researchers have analyzed population dynamics and displacements around the Eurasian steppe.
The higher revenues were driven by a 38 percent increase in product sales, which include the company's Epi proColon blood-based colorectal cancer screening test.
CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.
In a note to investors, Cowen analyst Doug Schenkel called the decision "odd," and wondered if there would be more to come.
Stanford University's Eilon Sharon used CRISPeY to conduct a genome-wide precise editing study to study the fitness consequences of variants found in different yeast strains.
The revenue growth was driven by an increase in collaboration revenues, which offset declines in product sales and lab services revenues.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, driven by growth in both its Life Science and Clinical Diagnostics businesses.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.
The company's total revenues were $23.1 million, supported by growth across the firm's instrument and consumables sales, and its research collaboration business.
Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.
With the Series B funding, Sytenkabio will consolidate its headquarters in Seoul, validate its technology, and look to expand into international markets.
Researchers used UK Biobank data to uncover genetic loci — many linked to pigmentation processes, but also novel ones — associated with being able to tan.
The Australian Genomics Health Futures Mission will include a series of studies to tackle rare diseases and cancers.
The funding will support the university's MRC Human Genetics Unit, which is investigating the genetic underpinnings of human health and disease.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.